K A Salters1,2, A Cescon1,3, W Zhang1, G Ogilvie4,5, M C M Murray4,6,7, A Coldman8, J Hamm8, C G Chiu9, J S G Montaner1,4, S M Wiseman9, D Money4,6,7, N Pick4,6,7, R S Hogg1,2. 1. BC Centre for Excellence in HIV/AIDS, Vancouver, Canada. 2. Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. 3. Northern Ontario School of Medicine, Sudbury, Canada. 4. Faculty of Medicine, University of British Columbia, Vancouver, Canada. 5. BC Centre for Disease Control, Vancouver, Canada. 6. BC Women's Hospital and Health Centre, Vancouver, Canada. 7. Women's Health Research Institute, Vancouver, Canada. 8. BC Cancer Agency, Vancouver, Canada. 9. Department of Surgery, St Paul's Hospital & University of British Columbia, Vancouver, Canada.
Abstract
OBJECTIVES: We used population-based data to identify incident cancer cases and correlates of cancer among women living with HIV/AIDS in British Columbia (BC), Canada between 1994 and 2008. METHODS: Data were obtained from a retrospective population-based cohort created from linkage of two province-wide databases: (1) the database of the BC Cancer Agency, a province-wide population-based cancer registry, and (2) a database managed by the BC Centre for Excellence in HIV/AIDS, which contains data on all persons treated with antiretroviral therapy in BC. This analysis included women (≥ 19 years old) living with HIV in BC, Canada. Incident cancer diagnoses that occurred after highly active antiretroviral therapy (HAART) initiation were included. We obtained a general population comparison of cancer incidence among women from the BC Cancer Agency. Bivariate analysis (Pearson χ(2) , Fisher's exact or Wilcoxon rank-sum test) compared women with and without incident cancer across relevant clinical and sociodemographic variables. Standardized incidence ratios (SIRs) were calculated for selected cancers compared with the general population sample. RESULTS: We identified 2211 women with 12 529 person-years (PY) of follow-up who were at risk of developing cancer after HAART initiation. A total of 77 incident cancers (615/100 000 PY) were identified between 1994 and 2008. HIV-positive women with cancer, in comparison to the general population sample, were more likely to be diagnosed with invasive cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma and Kaposi's sarcoma and less likely to be diagnosed with cancers of the digestive system. CONCLUSIONS: This study observed elevated rates of cancer among HIV-positive women compared to a general population sample. HIV-positive women may have an increased risk for cancers of viral-related pathogenesis.
OBJECTIVES: We used population-based data to identify incident cancer cases and correlates of cancer among women living with HIV/AIDS in British Columbia (BC), Canada between 1994 and 2008. METHODS: Data were obtained from a retrospective population-based cohort created from linkage of two province-wide databases: (1) the database of the BC Cancer Agency, a province-wide population-based cancer registry, and (2) a database managed by the BC Centre for Excellence in HIV/AIDS, which contains data on all persons treated with antiretroviral therapy in BC. This analysis included women (≥ 19 years old) living with HIV in BC, Canada. Incident cancer diagnoses that occurred after highly active antiretroviral therapy (HAART) initiation were included. We obtained a general population comparison of cancer incidence among women from the BC Cancer Agency. Bivariate analysis (Pearson χ(2) , Fisher's exact or Wilcoxon rank-sum test) compared women with and without incident cancer across relevant clinical and sociodemographic variables. Standardized incidence ratios (SIRs) were calculated for selected cancers compared with the general population sample. RESULTS: We identified 2211 women with 12 529 person-years (PY) of follow-up who were at risk of developing cancer after HAART initiation. A total of 77 incident cancers (615/100 000 PY) were identified between 1994 and 2008. HIV-positive women with cancer, in comparison to the general population sample, were more likely to be diagnosed with invasive cervical cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma and Kaposi's sarcoma and less likely to be diagnosed with cancers of the digestive system. CONCLUSIONS: This study observed elevated rates of cancer among HIV-positive women compared to a general population sample. HIV-positive women may have an increased risk for cancers of viral-related pathogenesis.
Authors: Sergio Serrano-Villar; Félix Gutiérrez; Celia Miralles; Juan Berenguer; Antonio Rivero; Esteban Martínez; Santiago Moreno Journal: Open Forum Infect Dis Date: 2016-05-12 Impact factor: 3.835
Authors: Connie G Chiu; Danielle Smith; Kate A Salters; Wendy Zhang; Steve Kanters; David Milan; Julio S G Montaner; Andy Coldman; Robert S Hogg; Sam M Wiseman Journal: BMC Cancer Date: 2017-04-14 Impact factor: 4.430
Authors: Ioana A Nicolau; Tony Antoniou; Jennifer D Brooks; Rahim Moineddin; Curtis Cooper; Michelle Cotterchio; Jennifer L Gillis; Claire E Kendall; Abigail E Kroch; Joanne D Lindsay; Colleen Price; Kate Salters; Marek Smieja; Ann N Burchell Journal: CMAJ Open Date: 2022-07-19